ClinicalTrials.gg
RecruitingNCT06413433ENGAGEUpdated Jul 28, 2026

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

A Phase 3 interventional study of Solriamfetol 150 mg and Solriamfetol 300 mg in Binge-Eating Disorder, sponsored by Axsome Therapeutics, Inc.. Recruiting at 45 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Planned enrollment
6th of 112
450 · median 67
Started
2024
with 7 others
Phase 3
15 of 122
2 open now
Primary completion
2026-12
later than 6 of 27 live
Registered
101st of 122
by date

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 6th largest by planned enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2024, is one of 15 in phase 3, reaches primary completion later than 6 of the 27 other live ones, and was the 101st registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.

Read the detailed description

Eligible subjects must have a diagnosis of BED according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to receive solriamfetol (150 or 300 mg) or placebo, once daily for 12 weeks.

03

Conditions studied

  • Binge-Eating Disorder

Browse trials for

Keywords

  • Binge eating disorder
  • BED
  • Solriamfetol
  • Sunosi
  • Axsome
  • Non-stimulant therapy
  • Dopamine norepinephrine reuptake inhibitor
  • Trace amine-associated receptor 1 (TAAR1) agonist
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of BED according to criteria.
  • Provides written to participate in the study before the conduct of any study procedures.
  • Male or female, aged 18 to 55 inclusive.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Solriamfetol 150 mg

    Up to 12 weeks

    Drug: Solriamfetol 150 mg

  • Experimental
    Solriamfetol 300 mg

    Up to 12 weeks

    Drug: Solriamfetol 300 mg

  • Placebo comparator
    Placebo

    Up to 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 12 in number of binge eating episodes

    Time frame: 12 weeks

07

Study locations

38 of 45 sites recruiting
  • Clinical Research Site
    Encino, California 91316, United States
    Recruiting
  • Clinical Research Site
    Garden Grove, California 92845, United States
    Recruiting
  • Clinical Research Site
    Long Beach, California 90806, United States
    Recruiting
  • Clinical Research Site
    Mission Viejo, California 92691, United States
    Recruiting
  • Clinical Research Site
    San Diego, California 92103, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Santa Ana, California 92705, United States
    Recruiting
  • Clinical Research Site
    Walnut Creek, California 94596, United States
    Recruiting
  • Clinical Research Site
    West Covina, California 91790, United States
    Recruiting
  • Clinical Research Site
    Colorado Springs, Colorado 80910, United States
    Recruiting
  • Clinical Research Site
    Cromwell, Connecticut 06416, United States
    Recruiting
  • Clinical Research Site
    Clermont, Florida 34711, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Fort Myers, Florida 33912, United States
    Recruiting
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
    Recruiting
  • Clinical Research Site
    Lauderhill, Florida 33319, United States
    Recruiting
  • Clinical Research Site
    Miami, Florida 33145, United States
    Recruiting
  • Clinical Research Site
    Miami, Florida 33176, United States
    Recruiting
  • Clinical Research Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Clinical Research Site
    Miami Lakes, Florida 33016, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Orlando, Florida 32801, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32806, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Marietta, Georgia 30060, United States
    Recruiting
  • Clinical Research Site
    Overland Park, Kansas 66210, United States
    Recruiting
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
    Recruiting
  • Clinical Research Site
    Methuen, Massachusetts 01844, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Clinical Research Site
    Cherry Hill, New Jersey 08002, United States
    Recruiting
  • Clinical Research Site
    Princeton, New Jersey 08540, United States
    Recruiting
  • Clinical Research Site
    Mount Kisco, New York 10549, United States
    Recruiting
  • Clinical Research Site
    New York, New York 10128, United States
    Recruiting
  • Clinical Research Site
    Raleigh, North Carolina 27607, United States
    Recruiting
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
    Recruiting
  • Clinical Research Site
    Mason, Ohio 45040, United States
    Recruiting
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
    Recruiting
  • Clinical Research Site
    North Canton, Ohio 44720, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Portland, Oregon 97210, United States
    Recruiting
  • Clinical Research Site
    Allentown, Pennsylvania 18104, United States
    Recruiting
  • Clinical Research Site
    Media, Pennsylvania 19063, United States
    Recruiting
  • Clinical Research Site
    Greenville, South Carolina 29615, United States
    Recruiting
  • Clinical Research Site
    North Charleston, South Carolina 29405, United States
    Recruiting
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
    Recruiting
  • Clinical Research Site
    Austin, Texas 73787, United States
    Recruiting
  • Clinical Research Site
    Austin, Texas 78731, United States
    Recruiting
  • Clinical Research Site
    Dallas, Texas 75231, United States
    Recruiting
  • Clinical Research Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Clinical Research Site
    Draper, Utah 84020, United States
    Terminated

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
Apr 26, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06413433
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Apr 26, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Study Director
Contact
sol-bed-301@axsome.com
212-332-5061

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion